SEC Form 4 · accession 0001567619-18-008702
Cigna Group · CI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew G Manders
Officer — President, Strategy & Solution
Period of report
Dec 20, 2018
Accepted (ET)
Dec 26, 2018 · 7:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001739940
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 Par ValueF3,F1,F2 | Dec 20, 2018 | A | 37,777 | $0.00 | A | 37,777 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F5,F4 | $78.035 | Dec 20, 2018 | A | 39,038 | A | — | Feb 26, 2024 | Common Stock, $0.01 Par Value | 39,038 | 39,038 | D |
| Employee Stock Option (Right to Buy)F5,F4 | $120.895 | Dec 20, 2018 | A | 30,229 | A | — | Feb 25, 2025 | Common Stock, $0.01 Par Value | 30,229 | 30,229 | D |
| Employee Stock Option (Right to Buy)F5,F4 | $139.22 | Dec 20, 2018 | A | 34,035 | A | — | Mar 1, 2026 | Common Stock, $0.01 Par Value | 34,035 | 34,035 | D |
| Employee Stock Option (Right to Buy)F5,F4 | $149.135 | Dec 20, 2018 | A | 28,038 | A | — | Feb 28, 2027 | Common Stock, $0.01 Par Value | 28,038 | 28,038 | D |
Explanation of responses
- F1Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)
- F2(continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
- F3Includes 2,352 restricted shares acquired in the Merger.
- F4This option was fully vested and exercisable at the time of the Merger.
- F5In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.